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Breast-conserving surgery (BCS) is commonly used to treat 
women with ductal carcinoma in situ (DCIS) and has been shown 
to be efficacious in reducing breast cancer mortality (1–4). Because 
BCS spares most of the breast, it is often considered to be most 
consistent with women’s preferences and improved quality of life 
(5–8). Although BCS for DCIS is an effective and safe alternative 
to mastectomy for women wanting to preserve their breasts, 
women continue to be at risk for recurrences in the ipsilateral 
breast. Up to 20% of women with DCIS will have a recurrence 
within 5 years, and about half of the recurrences will be invasive 
(1–3). Because women treated with BCS continue to undergo 
clinical and radiographic surveillance, partly due to heightened 
patient and/or clinician concerns (9,10), more women are likely to 
be at risk for subsequent diagnostic evaluations than those who are 
ultimately diagnosed with a recurrence.
Previous studies have reported a substantial risk of re-excisions 
following initial attempts at BCS, often leading to mastectomy 
(11–13). However, to our knowledge, no studies have reported the 
rates of subsequent diagnostic evaluations for recurrent breast 
cancer years after BCS. The clinical consequences of both diag-
nostic mammograms and invasive procedures are important 
because they may lead to anxiety and potential overtreatment. 
Understanding the likelihood of additional diagnostic imaging and 
invasive procedures may contribute to women’s decision making 
about treatment. We determined the proportions, predictors, and 
cumulative incidence of diagnostic mammograms and ipsilateral 
invasive procedures experienced by a large cohort of women with 
DCIS who were treated with BCS between 1990 and 2001 and 
followed for up to 10 years.
Methods
Setting and Participants
The study was conducted under the auspices of the National Cancer 
Institute–funded Cancer Research Network, a consortium of 11 
(now 14) integrated health-care delivery systems with more than 11 
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grams and ipsilateral invasive procedures following the initial breast excision to treat DCIS, estimated the 
10-year cumulative incidence of these procedures, and determined hazard ratios for both types of procedures 
with Cox regression modeling. All statistical tests were two-sided.
 Results Over 10 years, 907 women (30.8%) had 1422 diagnostic mammograms and 1813 (61.5%) had 2305 ipsilateral 
invasive procedures. Diagnostic mammograms occurred in 7.3% of women in the first 6 months and continued 
at a median annual rate of 4.3%. Ipsilateral invasive procedures occurred in 51.5% of women in the first 
6 months and continued at a median annual rate of 3.1%. The estimated 10-year cumulative risk of having at 
least one diagnostic mammogram after initial DCIS excision was 41.0% (95% confidence interval [CI] = 38.5% to 
43.5%); at least one invasive procedure, 65.7% (95% CI = 63.7% to 67.8%); and either event, 76.1% (95% CI = 
74.1% to 78.1%). Excluding events in the first 6 months following initial DCIS excision, corresponding risks were 
36.4% (95% CI = 33.8% to 39.0%) for diagnostic mammograms, 30.4% (95% CI = 26.9% to 33.8%) for invasive 
procedures, and 49.5% (95% CI = 45.6% to 53.5%) for either event.
 Conclusions Women with DCIS treated with BCS continue to have diagnostic and invasive breast procedures in the con-
served breast over an extended period. The frequency of ongoing diagnostic breast evaluations should be 
included in discussions about treatment.
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million enrollees (14). Three sites contributed patients to this study 
including Kaiser Permanente Northern California, Kaiser 
Permanente Southern California, and Harvard Pilgrim Health 
Care; all three Institutional Review Boards approved the study.
The original cohort was assembled to study risk factors for 
DCIS recurrence after BCS, and methods have been previously 
described (15,16). Briefly, we identified women who were diag-
nosed with an index unilateral DCIS between 1990 and 2001, were 
85 years or younger at diagnosis, and had no prior breast cancer or 
another invasive cancer (except non-melanoma skin cancer). 
Women were excluded if the index DCIS was bilateral, the majority 
of care for DCIS was obtained outside the participating sites, they 
were followed for less than 6 months after diagnosis, they were 
diagnosed with invasive breast cancer, or had mastectomy within 
6 months of the index DCIS.
Data Sources
As previously described (15,16), we used Surveillance, 
Epidemiology, and End Results (SEER)–affiliated cancer regis-
tries to identify women at Kaiser Permanente Northern 
California and Southern California. At Harvard Pilgrim Health 
Care, we initially identified women using claims data followed by 
review of electronic outpatient medical records. At all sites, 
trained abstractors reviewed the medical records of potentially 
eligible patients to confirm the diagnosis, laterality, and treat-
ment of the index DCIS, and to obtain information on patient 
and clinical factors at diagnosis. Standard quality control 
measures were used, which included training of the medical 
record abstractors, the standardization of data collection and 
processing, ongoing monitoring to ensure timeliness and accuracy 
of study protocols, and an independent abstraction of 10% of the 
charts by a second abstractor.
Definitions of Diagnostic Mammograms and Invasive 
Procedures
Beginning with the date of the first breast excision to treat DCIS 
(hereafter called the index DCIS excision), all diagnostic mammo-
grams, invasive breast procedures, and breast cancer events were 
recorded for up to 10 years for each woman. We defined diagnos-
tic mammograms as mammograms obtained for new symptoms 
and/or new abnormalities on a prior breast examination or mam-
mogram and routine surveillance mammograms as those done in 
the absence of any new symptoms, signs, or abnormalities. In this 
analysis, we include only diagnostic mammograms. The laterality 
of the diagnostic mammogram was not initially abstracted from 
the medical records; medical record review and automated codes 
were later used to classify mammograms obtained only on the 
contralateral breast at two sites (Kaiser Permanente Northern 
California and Harvard Pilgrim Health Care). Detailed informa-
tion was collected on all invasive breast procedures including 
laterality, type (fine needle aspiration, core biopsy, excisional 
biopsy, and mastectomy), dates, and pathology results. Indications 
for invasive procedures were not abstracted.
Covariates
We included the following patient characteristics recorded at the 
time of DCIS diagnosis: age (25–49, 50–59, 60–69, and 70–84 
years), race (white, Asian, black, Hispanic, other, unknown), body 
mass index (<25, 25–29, ≥30 kg/m2, unknown), menopausal status 
(postmenopausal, pre/perimenopausal, unknown), diabetes mellitus 
(type I or II) (yes, no, unknown), family history of breast cancer 
(yes, no, unknown), and use of menopausal hormone therapy 
(former, current, never, unknown). Body mass index was obtained 
using the weight and height recorded before and closest to the 
index DCIS excision. Postmenopausal status was defined as having 
the last menstrual period noted in the chart 12 or more months 
before diagnosis, having had surgical menopause, having docu-
mentation of postmenopausal status in the medical record, or age 
of at least 60 years at diagnosis. Family history was defined as 
having breast cancer in a first-degree relative noted at or within 
6 months of DCIS diagnosis.
Statistical Analyses
First, we described the patient cohort, including characteristics at 
the time of DCIS diagnosis, year of diagnosis, and initial treat-
ment. We then recorded all diagnostic mammograms and inva-
sive ipsilateral procedures after the index DCIS excision until 
one of the following events: recurrent ipsilateral DCIS and/or 
invasive breast cancer, contralateral DCIS and/or invasive breast 
cancer, last follow-up date, date of death, 10 years after index 
CONTEXTS AND CAVEATS
Prior knowledge
Breast-conserving surgery (BCS) has been shown to be an effective 
alternative to mastectomy in the treatment of ductal carcinoma in 
situ (DCIS). However, the likelihood of additional diagnostic mam-
mograms and invasive procedures following BCS is unknown.
Study design
Women treated with BCS between 1990 and 2001 at three large 
health-care systems were followed for up to 10 years. The percent-
ages and cumulative incidence of diagnostic mammograms and 
ipsilateral invasive procedures following first breast excision were 
calculated.
Contribution
Over 10 years, the cumulative risk of having at least one diagnostic 
mammogram was 41%, and the risk of at least one invasive proce-
dure was 66% after initial treatment with BCS.
Implications
Although treatment with BCS is a reasonable option for women 
with DCIS, invasive procedures and diagnostic evaluation for pos-
sible recurrent breast cancer can extend over a long period fol-
lowing initial excision and treatment.
Limitations
Women who had mastectomy within 6 months of the first DCIS 
excision were excluded. Thus, the rate of imaging and invasive 
procedures in the first 6 months may have been underestimated. 
Other imaging procedures such as breast magnetic resonance im-
aging were not evaluated. The cohort was drawn from women 
enrolled in three integrated health-care delivery systems, and 
therefore the findings may not be applicable to other settings.
From the Editors
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DCIS excision, or the end of the study (February 24, 2006), 
whichever occurred first. When we excluded contralateral mam-
mograms obtained by the women at the two sites (n = 105, 7.4%), 
the overall results were similar; therefore, the entire cohort was 
included in the analysis.
Second, we calculated the percentage of women who had at 
least one diagnostic mammogram and/or ipsilateral invasive proce-
dure and mean number of procedures per woman for each of the 
10 years of follow-up, beginning immediately after the index DCIS 
excision. Point and interval estimates of hazard ratios (HR) for 
diagnostic mammograms and invasive procedures in relation to 
patient and treatment factors were obtained with Cox proportional 
hazards regression models. Wald tests were conducted to calculate 
two-sided statistical significance. The proportional hazards assump-
tion was tested by fitting models containing cross-product terms 
between time (log) and patient and treatment factors. In general, 
we found no evidence of non-proportionality in hazard ratios, 
although several variables did meet the 5% significance level cri-
teria. Further examination of time-stratified analyses demon-
strated that heterogeneity was relatively modest and not of clinical 
significance; we therefore present results without stratification 
on time.
We estimated the cumulative incidence of having at least one 
diagnostic mammogram, ipsilateral invasive procedure, or either 
event over the 10-year period after the index DCIS excision, taking 
into account the risk of experiencing the other events of interest. 
These models distinguish between patients who are still alive and 
those who have already failed from competing causes and allow 
direct inference regarding the effects of covariates on the cumulative 
incidence function (17). In this case, in estimating the cumulative 
incidence for diagnostic mammograms, the likelihood of experi-
encing an ipsilateral invasive procedure during this period is taken 
into account.
Because diagnostic evaluations and re-excisions are common 
immediately following an index DCIS excision, we also calcu-
lated the cumulative incidence of each of these procedures start-
ing 6 months after the index DCIS excision. To assess the rates 
of recurrences compared with the rates of diagnostic evalua-
tions, we used the same methodology to estimate the cumulative 
incidence of recurrent ipsilateral DCIS and/or invasive breast 
cancer over the 10-year period. All analyses were done using 
SAS v. 9.1 (SAS Institute Inc, Cary, NC). All statistical tests 
were two-sided.
Results
Patient Selection and Characteristics
A total of 3668 potentially eligible DCIS patients were identified 
for the cohort study. Of these, 520 were ineligible for one or more 
of the following reasons: miscoding of DCIS in the tumor registry 
(n = 97), prior breast or other cancer (n = 216), bilateral breast 
cancer at diagnosis (n = 29), 85 years of age or older at diagnosis 
(n = 15), or had less than 6 months of follow-up (mastectomy 
within 6 months [n = 96], death within 6 months [n = 6], or not a 
member at diagnosis or left the participating institution within 
6 months [n = 92]). In addition, medical records were unavailable on 
82 patients and 29 did not have complete information on adjuvant 
therapy. Of the 3037 women determined to be eligible by chart 
review, 42 had no pathology report confirming breast-conserving 
therapy, and an additional 47 had no pathology-confirmed DCIS, 
leaving 2948 patients for this analysis.
The women had a mean age of 58.2 years (SD = 11.4 years) and 
a median follow-up of 4.8 years (range = 0.5–15.7 years). 
Approximately 42% (n = 1247) were treated with BCS alone, 42% 
(n = 1243) with adjuvant radiation, 11% (n = 328) with both adju-
vant radiation and tamoxifen, and 4% (n = 130) with tamoxifen 
alone (Table 1). Eleven percent (n = 325) of the women had a local 
recurrence, 173 ipsilateral DCIS and 152 ipsilateral invasive 
breast cancer.
Table 1. Characteristics of the 2948 women with DCIS treated with 
breast-conserving surgery*
Characteristic No. (%)
Age at diagnosis, y
 25–49 753 (25.5)
 50–59 842 (28.6)
 60–69 790 (26.8)
 70–84 563 (19.1)
Diagnosis year
 1990–1991 247 (8.4)
 1992–1993 347 (11.8)
 1994–1995 441 (15.0)
 1996–1997 553 (18.8)
 1998–1999 655 (22.2)
 2000–2001 705 (23.9)
Race
 White 2015 (68.4)
 Asian 353 (12.0)
 Black 285 (9.7)
 Hispanic 252 (8.5)
 Other 7 (0.2)
 Unknown 36 (1.2)
BMI at diagnosis, kg/m2
 <25 (normal) 1107 (37.6)
 25–29 (overweight) 900 (30.5)
 ≥30 (obese) 647 (21.9)
 Unknown 294 (10.0)
Menopausal status at diagnosis
 Postmenopausal 2033 (69.0)
 Pre/perimenopausal 849 (28.8)
 Unknown 66 (2.2)
Diabetes at diagnosis
 Yes 213 (7.2)
 No 2729 (92.6)
 Unknown 6 (0.2)
Family history of breast cancer at diagnosis
 Yes 518 (17.6)
 No 2362 (80.1)
 Unknown 68 (2.3)
Menopausal hormone therapy use at diagnosis
 Former 1230 (41.7)
 Current 635 (21.5)
 Never 839 (28.5)
 Unknown 244 (8.3)
Treatment of DCIS
 Breast-conserving surgery alone 1247 (42.3)
 Breast-conserving surgery/radiation 1243 (42.2)
 Breast-conserving surgery/radiation/tamoxifen 328 (11.1)
 Breast-conserving surgery/tamoxifen 130 (4.4)
* N = 2948; BMI = body mass index; DCIS = ductal carcinoma in situ.
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Diagnostic Mammograms and Ipsilateral Invasive 
Procedures
Over 10 years of follow-up, 907 (30.8%) of the women had 1422 
diagnostic mammograms (Table 2) to evaluate new abnormalities on 
breast examination or surveillance mammogram (n = 1213 events, 
85.3%) or new symptoms (n = 209 events, 14.7%). Most women 
(61.5%, n = 1813) had at least one ipsilateral invasive procedure over 
the study period (Table 2). Of the 2305 procedures, excisional biopsies 
were the most common (84.0%), whereas core biopsies accounted for 
8.4% and fine needle aspirations for 3.6%. Rates of diagnostic mam-
mograms varied by treatment, with highest rates observed among 
women treated with adjuvant radiation alone (34.9%) and lowest 
among those treated with adjuvant tamoxifen alone (22.3%) (Table 2). 
Similar results were found for invasive procedures, with 64.7% occur-
ring among women treated with adjuvant radiation alone and 49.2% 
among those treated with adjuvant tamoxifen alone (Table 2).
Diagnostic mammograms were common immediately after the 
index DCIS excision (Table 3), occurring in 7.3% of women 
during the first 6 months and 5.3% of women in the second 6 
months. However, diagnostic mammograms were most commonly 
used during year 2, occurring in 11.4% of women (2.5% of women 
had more than one diagnostic mammogram). Following the first 6 
months, diagnostic mammograms occurred at an annual median of 
4.3% (range = 3.5%–11.4%).
In contrast to diagnostic mammograms, ipsilateral invasive 
breast procedures were most common in the first 6 months of 
follow-up, with 51.5% of women undergoing at least one proce-
dure (48.6% undergoing one procedure and 2.9% undergoing 
more than one procedure; Table 4). Invasive procedures were 
much less common during the rest of the 10-year follow-up but 
continued to occur with an annual median rate of 3.1% (range = 
1.8%–4.8%).
Table 2. Diagnostic mammograms and ipsilateral invasive procedures after index DCIS excision in 2948 women over 10 years of 
follow-up*
Treatment
No. (%)
Diagnostic  
mammograms
Any ipsilateral  
invasive procedures
Excisional  
biopsy
Core  
biopsy FNA Mastectomy Other/Unknown
All women (N = 2948)       
 Patients† 907 (30.8) 1813 (61.5) 1641 (55.7) 175 (5.9) 70 (2.4) 34 (1.2) 59 (2.0)
 Events‡ 1422 (100) 2305 (100) 1936 (84.0) 193 (8.4) 82 (3.6) 34 (1.5) 60 (2.6)
BCS only (N = 1247)       
 Patients 337 (27.0) 760 (60.9) 671 (53.8) 90 (7.2) 37 (3.0) 23 (1.8) 21 (1.7)
 Events 527 (100) 996 (100) 807 (81.0) 101 (10.1) 43 (4.3) 23 (2.3) 22 (2.2)
BCS with radiation (N = 1243)       
 Patients 434 (34.9) 804 (64.7) 739 (59.5) 66 (5.3) 29 (2.3) 8 (0.6) 27 (2.2)
 Events 679 (100) 1007 (100) 864 (85.8) 73 (7.2) 35 (3.5) 8 (0.8) 27 (2.7)
BCS with XRT + TAM (N = 328)       
 Patients 107 (32.6) 185 (56.4) 174 (53.0) 12 (3.7) 4 (1.2) 1 (0.3) 6 (1.8)
 Events 167 (100) 226 (100) 203 (89.8) 12 (5.3) 4 (1.8) 1 (0.4) 6 (2.7)
BCS with TAM (N = 130)       
 Patients 29 (22.3) 64 (49.2) 57 (43.8) 7 (5.4) 0 (0) 2 (1.5) 5 (3.8)
 Events 49 (100) 76 (100) 62 (81.6) 7 (9.2) 0 (0) 2 (2.6) 5 (6.6)
* BCS = breast-conserving surgery; FNA = fine needle aspiration; TAM = adjuvant tamoxifen; XRT = adjuvant radiation treatment.
† Percent calculated from total number of women in cohort and in treatment group.
‡ Percent calculated from total number of events for entire cohort and for each treatment group.
Table 3. Diagnostic mammography after DCIS excision by year of follow-up*
Year  
of follow-up
Total No. of  
women
0 diagnostic  
mammograms, %
At least one diagnostic  
mammogram, No. (%)
1 diagnostic  
mammogram, %
2-4 diagnostic  
mammograms, %
Diagnostic  
mammograms, total 
(mean per patient)
1 (0–6 mo) 2948 92.7 214 (7.3) 6.5 0.8 241 (0.08)
1 (7–12 mo) 2937 94.7 157 (5.3) 4.9 0.5 171 (0.06)
2 2821 88.6 321 (11.4) 8.9 2.5 398 (0.14)
3 2593 93.8 162 (6.2) 5.3 0.9 186 (0.07)
4 2296 95.8 97 (4.2) 3.6 0.6 112 (0.05)
5 1813 95.1 89 (4.9) 4.2 0.7 105 (0.06)
6 1378 95.6 60 (4.4) 3.8 0.6 69 (0.05)
7 1051 96.4 38 (3.6) 3.3 0.3 42 (0.04)
8 879 95.7 38 (4.3) 4.0 0.3 41 (0.05)
9 752 96.1 29 (3.9) 3.3 0.5 34 (0.05)
10 571 96.5 20 (3.5) 3.0 0.5 23 (0.04)
* N = 2948. DCIS = ductal carcinoma in situ.
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Cumulative Incidence of Diagnostic Mammograms, 
Ipsilateral Invasive Procedures, and Recurrent Breast 
Cancer
Using cumulative incidence curves, we estimated that following 
index DCIS excision, 41.0% (95% CI = 38.5% to 43.5%) of the 
women had at least one diagnostic mammogram, 65.7% (95% 
CI = 63.7% to 67.8%) had at least one invasive procedure, and 
76.1% (95% CI = 74.1% to 78.1%) had either event (Figure 1, A). 
Ipsilateral invasive procedures were very common in the first 
6 months after the index DCIS excision, when 51.3% of the 
women (95% CI = 49.5% to 53.1%) had at least one or more. 
Whereas diagnostic mammograms were also common during the 
first 6 months, the cumulative incidence of 7.3% (95% CI = 6.3% 
to 8.2%) was much lower than invasive procedures. When events 
occurring during the first 6 months following index DCIS excision 
were excluded, 36.4% (95% CI = 33.8% to 39.0%) of the women 
had at least one diagnostic mammogram over the following 
10 years; 30.4% (95% CI = 26.9% to 33.8%) had at least one inva-
sive procedure, and 49.5% (95% CI = 45.6% to 53.5%) had either 
a diagnostic mammogram or an invasive procedure (Figure 1, B). 
Over the 10-year follow-up, an estimated 8.0% (95% CI = 6.8% to 
9.3%) and 8.1% (95% CI = 6.7% to 9.5%) had recurrent DCIS or 
invasive cancer, respectively.
Factors Associated with Diagnostic Mammograms and 
Invasive Procedures
Users of menopausal hormones were more likely to undergo diag-
nostic mammograms than nonusers (HR of diagnostic mammo-
gram: former users, 1.24, 95% CI = 1.03 to 1.48, P = .022; current 
users, 1.32, 95% CI = 1.08 to 1.60, P = .005) (Table 5). Women 
who received adjuvant radiation treatment alone were more likely 
to undergo diagnostic mammograms (HR of diagnostic mammo-
gram = 1.19, 95% CI = 1.02 to 1.38, P = .023) and invasive proce-
dures (HR of invasive procedure = 1.15, 95% CI = 1.04 to 1.28, 
P = .006) following index DCIS excision than women who had 
BCS alone. Women aged 70 years and older were less likely to 
have invasive procedures (HR of invasive procedure = 0.73, 95% 
CI = 0.60 to 0.90, P = .002) than women under age 50. Although 
obesity was not related to diagnostic mammograms, obese women 
were less likely to undergo invasive procedures (HR of invasive 
procedure = 0.88, 95% CI = 0.78 to 0.99, P = .036). Family history 
and race were not related to either diagnostic procedure.
Discussion
We found that diagnostic mammograms and invasive breast 
procedures were common in the ipsilateral breast after BCS and 
Table 4. Ipsilateral invasive procedures after DCIS excision by year of follow-up*
Year of  
follow-up
Total No. of  
women
0 invasive  
procedures, %
At least one invasive  
procedure, No. (%)
1 invasive  
procedure, %
2–4 invasive  
procedures, %
Invasive procedures, 
total (mean per patient)
1 (0–6 mo) 2948 48.5 1518 (51.5) 48.6 2.9 1611 (0.55)
1 (7–12 mo) 2937 95.3 137 (4.7) 4.3 0.4 149 (0.05)
2 2821 95.2 134 (4.8) 4.2 0.6 151 (0.05)
3 2593 95.5 116 (4.5) 4.0 0.4 130 (0.05)
4 2296 96.9 71 (3.1) 2.8 0.3 77 (0.03)
5 1813 97.0 55 (3.0) 2.6 0.4 63 (0.03)
6 1378 97.8 31 (2.2) 2.1 0.1 34 (0.02)
7 1051 96.8 34 (3.2) 2.9 0.3 37 (0.04)
8 879 97.2 25 (2.8) 2.7 0.1 26 (0.03)
9 752 97.9 16 (2.1) 2.0 0.1 17 (0.02)
10 571 98.2 10 (1.8) 1.8 0.0 10 (0.02)
* N = 2948. Includes fine needle aspiration, needle/core biopsy, excisional biopsy, and mastectomy. DCIS = ductal carcinoma in situ.
A
B
DM/IP
DM
IP
BCa
DCIS
6 months 
DM/IP 
IP 
DM 
BCa
DCIS
-
-
Figure 1. Cumulative incidence of at least one diagnostic mammogram, 
ipsilateral invasive procedure, recurrent DCIS, or invasive breast cancer 
in women over 10 years following DCIS excision. This approach esti-
mates the risk of experiencing an event while taking into account the 
risk of experiencing the other events of interest during this period (17). 
A) Follow-up begins at the time of index DCIS excision. B) Follow-up 
begins 6 months after index DCIS excision. BCa = recurrent ipsilateral 
invasive breast cancer; DCIS = recurrent ipsilateral ductal carcinoma in 
situ; DM = diagnostic mammogram; IP = invasive procedure. DM/IP, 
dotted and dashed line; IP, bold dashed line; DM, dotted line; BCa, bold 
solid line; DCIS, light dashed line. All statistical tests were two-sided.
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continued for as long as 10 years. Overall, we estimated that about 
three quarters of the women were at risk for at least one of these 
diagnostic procedures during the first decade after BCS, with one-
third of the women experiencing a diagnostic mammogram and 
two-thirds, an invasive breast procedure. Because approximately 
half of the women had at least one invasive procedure (usually a 
re-excision) shortly after the index DCIS excision, we also esti-
mated the cumulative incidence of diagnostic procedures starting 
6 months later. We found that when using this cut point, about 
50% of the women were at risk for at least one subsequent proce-
dure, 36% for at least one diagnostic mammogram, and 30% for at 
least one invasive procedure.
Re-excisions to obtain clear margins present a unique burden to 
women undergoing BCS because women who initially choose to 
undergo mastectomy following diagnosis are not usually subject to 
these repeat procedures. Our findings are consistent with those 
of others (11) who found that between 20% and 70% of women 
undergoing BCS have repeat excisions to attain clear margins. 
A recent study (12) that included 714 women with in situ and 
invasive breast cancer found that 51% of the women had one 
additional excision, 42% had two excisions, and approximately 7% 
had three. Notably, 11% of the women ultimately had a mastec-
tomy. Likewise, Morrow et al. (13) found that approximately 38% 
of 1459 women who initially received BCS had repeat excisions, 
Table 5. Relationship of patient and treatment factors to the risk of diagnostic mammograms and ipsilateral invasive procedures after 
index DCIS excision in multivariable analyses*
Factor
Risk of diagnostic  
mammograms
Risk of ipsilateral invasive  
procedures
HR (95% CI) Overall P HR (95% CI) Overall P
Age at diagnosis, y  .49  .004
 25–49 1.00 (referent)  1.00 (referent)
 50–59 0.92 (0.74 to 1.14)  0.94 (0.81 to 1.10)
 60–69 0.87 (0.67 to 1.13)  0.92 (0.76 to 1.10)
 70–84 0.80 (0.60 to 1.07)  0.73 (0.60 to 0.90)†
Diagnosis year  .005  .006
 1990–1991 1.00 (referent)  1.00 (referent)
 1992–1993 0.84 (0.64 to 1.11)  1.09 (0.89 to 1.34)
 1994–1995 0.75 (0.58 to 0.98)‡  1.22 (1.01 to 1.48)‡
 1996–1997 0.83 (0.64 to 1.07)  1.28 (1.06 to 1.55)†
 1998–1999 1.15 (0.88 to 1.49)  1.12 (0.92 to 1.36)
 2000–2001 0.95 (0.72 to 1.25)  0.97 (0.79 to 1.18)
Race  .72  .20
 White 1.00 (referent)  1.00 (referent)
 Asian 0.96 (0.77 to 1.18)  1.02 (0.88 to 1.18)
 Black 0.98 (0.78 to 1.24)  1.16 (1.00 to 1.36)
 Hispanic 1.06 (0.84 to 1.34)  0.92 (0.77 to1.10)
 Other 0.61 (0.28 to 1.31)  0.84 (0.55 to 1.26)
BMI at diagnosis, kg/m2  .43  .10
 <25 (normal) 1.00 (referent)  1.00 (referent)
 25–29 (overweight) 1.01 (0.86 to 1.19)  0.96 (0.86 to 1.08)
 ≥30 (obese) 1.11 (0.94 to 1.30)  0.88 (0.78 to 0.99)‡
Menopausal status at diagnosis  .89  .49
 Postmenopausal 1.00 (referent)  1.00 (referent)
 Pre/perimenopausal 1.05 (0.84 to 1.32)  1.05(0.90 to 1.23)
Diabetes at diagnosis  .65  .24
 No 1.00 (referent)  1.00 (referent)
 Yes 1.02 (0.79 to 1.32)  0.90 (0.74 to 1.09)
Family history of breast cancer at diagnosis  .59  .08
 No 1.00 (referent)  1.00 (referent)
 Yes 1.07 (0.91 to 1.27)  1.13 (1.00 to 1.27)
Menopausal hormone therapy use at diagnosis  .03  .33
 None 1.00 (referent)  1.00 (referent)
 Former Use 1.24 (1.03 to 1.48)‡  1.03 (0.91 to 1.17)
 Current Use 1.32 (1.08 to 1.60)†  1.13 (0.99 to 1.30)
Treatment of DCIS  .08  .04
 BCS alone 1.00 (referent)  1.00 (referent)
 BCS/tamoxifen 0.87 (0.59 to 1.29)  0.96 (0.74 to 1.25)
 BCS/radiation 1.19 (1.02 to 1.38)‡  1.15 (1.04 to 1.28)†
 BCS/radiation/tamoxifen 1.16 (0.91 to 1.47)  1.05 (0.88 to 1.26)
* Analyses adjusted for diagnosis year; age, race, body mass index, menopausal status, diabetes, family history, menopausal hormone therapy use (all at the time 
of diagnosis); treatment of DCIS, year of follow-up and site. BCS = breast-conserving surgery; BMI = body mass index; CI = confidence interval; DCIS = ductal 
carcinoma in situ; HR = hazard ratio. All statistical tests were two-sided.
† P < .01.
‡ P < .05.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on A
ugust 13, 2013
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
620   Articles | JNCI Vol. 104, Issue 8  |  April 18, 2012
and 12% of all women who received BCS subsequently had 
mastectomy. Women with DCIS were most likely to undergo 
re-excisions compared with women with invasive cancers. Based on 
these data showing that women often undergo mastectomies fol-
lowing repeat excisions, our study may have underestimated the 
true frequency of early invasive procedures because we excluded 
women who had mastectomy within 6 months of diagnosis. 
Various intraoperative approaches, such as positron emission 
tomography, radioguided occult lesion localization, and near- 
infrared fluorescence optical imaging, aimed at reducing re-
excisions have been tested (11,18) but at this time are unlikely to 
be used in most clinical settings.
Diagnostic mammograms shortly following DCIS excision are 
commonly performed to check for remaining microcalcifications 
associated with DCIS. Later, diagnostic mammograms are used in 
follow-up of clinical and/or radiographic findings associated with 
breast tissue abnormalities that have been reported after surgery 
and/or breast radiation therapy (19). The latter is consistent with 
our finding that diagnostic mammograms were more common 
among those treated with adjuvant radiation therapy. Likewise, 
invasive procedures were also more common among women 
treated with adjuvant therapy than BCS alone. Similar to previous 
randomized controlled trials, we reported lower rates of DCIS 
recurrences in our cohort with the use of adjuvant therapy (16); 
however, it appears that adjuvant treatment may in fact be associ-
ated with increased rates of subsequent diagnostic imaging. 
Because radiation therapy use continues to increase, unless 
methods to differentiate between surgical and/or radiation-induced 
changes in the breast are developed, the incidence of invasive pro-
cedures may also increase.
Increased rates of diagnostic imaging and invasive procedures 
may be attributable to concerns about recurrences. Women with 
DCIS have high levels of anxiety about their diagnosis (10,20,21) 
and as a result, may be more vigilant about new breast symptoms 
and findings. We found that close to 15% of diagnostic mammo-
grams were attributable to new symptoms. Clinician attention to 
breast abnormalities among these women at substantial increased 
risk of local recurrence may also be heightened, resulting in addi-
tional diagnostic evaluations.
BCS has become the most common treatment for women with 
DCIS (1–4,13). However, recent data (22) show that mastectomy 
rates have again begun to increase, and the rates of contralateral 
prophylactic mastectomy among women with DCIS almost tripled 
between 1998 and 2003 (23). The reasons for these trends are not 
clear but may be related to the growing use of breast magnetic 
resonance imaging (MRI) and increased awareness of genetic 
testing (24). Women’s preferences also appear to have a role in the 
decision for BCS vs mastectomy (25–27); a recent study found that 
after women were informed about mortality, treatment, and recur-
rences after BCS and mastectomy, 35% chose mastectomy (28). We 
did not find any study reporting women’s choices after being informed 
about diagnostic procedures that may occur following initial 
treatment.
Our study also had some limitations. As noted earlier, we may 
have underestimated imaging and invasive procedures in the first 
6 months after DCIS excision because we excluded women who 
had mastectomy within 6 months of the index DCIS excision. We 
had incomplete information about the laterality of the diagnostic 
mammograms and may have overestimated their risk by including 
only mammograms of the contralateral breast, which may have 
occurred regardless of initial DCIS treatment. However, when we 
excluded contralateral mammograms at two sites (7.4%), the results 
were similar. Furthermore, we did not evaluate the use of other 
imaging procedures, such as breast MRI, which was rare during 
the study period. Because breast MRI use continues to increase, 
invasive procedures to investigate abnormal findings may become 
more common (29). Alternatively, it is also possible that additional 
imaging may reduce the use of surgical procedures. Finally, our 
cohort was drawn from women enrolled in three integrated health-
care delivery systems; therefore, our study findings may not be 
generalizable to other settings. However, unlike academic or 
research settings, these settings may better represent “real-world” 
clinical practice. Because our systems are integrated and continue 
to provide care for patients following diagnosis with low disen-
rollment rates (30), we were able to obtain comprehensive informa-
tion about our patients’ evaluations over time.
Breast-conserving treatment is a reasonable option for women 
with DCIS and results in similar long-term mortality outcomes as 
mastectomy; however, invasive procedures and diagnostic evalua-
tion workup for possible recurrent breast cancer extends over a 
long period following DCIS excision and treatment. The frequent 
need for re-excision among women choosing BCS warrants more 
scientific attention, including efforts to decrease its occurrence. 
However, decreasing early re-excisions and long-term diagnostic 
evaluations to detect recurrences among women at risk for recur-
rences remains a challenge. Although our findings do not directly 
address the relative benefits and harms of mastectomy vs BCS, 
they can inform women and their clinicians about the frequency of 
diagnostic imaging and invasive procedures following BCS and 
assist them in making treatment decisions. The fact that women 
undergoing BCS are likely to have diagnostic and invasive breast 
procedures in the conserved breast over an extended period of 
time is important and needs to be included in discussions about 
treatment options.
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